Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab

Conditions: Neoadjuvant Chemotherapy; Resectable Pancreatic Cancer Interventions: Drug: irinotecan liposome + oxaliplatin + 5-FU / LV; Drug: Adebellizumab Sponsors: Zhejiang University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials